Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac

• Main Authors: Caterina F. Ramogida (Author), Andrew K. H. Robertson (Author), Una Jermilova (Author), Chengcheng Zhang (Author), Hua Yang (Author), Peter Kunz (Author), Jens Lassen (Author), Ivica Bratanovic (Author), Victoria Brown (Author), Lily Southcott (Author), Cristina Rodríguez-Rodríguez (Author), Valery Radchenko (Author), François Bénard (Author), Chris Orvig (Author), Paul Schaffer (Author)
• Format: Book
• Published: SpringerOpen, 2019-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Actinium-225 (225Ac, t1/2 = 9.9 d) is a promising candidate radionuclide for use in targeted alpha therapy (TAT), though the currently limited global supply has hindered the development of a suitable Ac-chelating ligand and 225Ac-radiopharmaceuticals towards the clinic. We at TRI...